<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850418</url>
  </required_header>
  <id_info>
    <org_study_id>12592</org_study_id>
    <nct_id>NCT03850418</nct_id>
  </id_info>
  <brief_title>Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant</brief_title>
  <official_title>Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Henry Ford Health System</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies provide a rationale for administration of AZA after allo SCT for decreasing
      chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and
      help decrease rate of decreasing donor chimerism and hence decrease relapse without
      increasing GVHD
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">February 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 20, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of increase or stable donor chimerism</measure>
    <time_frame>one year</time_frame>
    <description>To determine the rate of increase or stable donor chimerism when using low dose azacitidine post allogenic stem cell transplant (SCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and myeloproliferative neoplasms (MPN) with documented low or decreasing donor chimerism</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Myeloid Malignancy</condition>
  <arm_group>
    <arm_group_label>AZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>azacitidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>azacitidine 32mg/m2 x 5 days every 28 days for minimum of 4 cycles if tolerated</description>
    <arm_group_label>AZA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with AML/MDS/MPN, CMML post Allogeneic SCT who experience any drop in total
             or myeloid chimerism any time after day 30, or their day 30 or day100 myeloid donor
             chimerism is below 98% without concurrent hematologic relapse (that is, patients with
             &lt;5% bone marrow blasts as obtained at that time point) will be offered treatment with
             azacitidine

          2. &gt;=30 -180 days post SCT and patients must have ANC&gt; 1000, PLT &gt; 50,000

          3. Age 18-75 years old

          4. Performance score of at least 70% by Karnofsky

          5. Adequate kidney and liver function as demonstrated by:

               1. Creatinine clearance should be &gt;60 ml/min

               2. Total Bilirubin &lt;1.5, ALT/AST/Alk Phos &lt; 2.5 x normal. No evidence of chronic
                  active hepatitis or cirrhosis.

          6. Negative Beta HCG test in a woman with child bearing potential, defined as not
             post-menopausal for 12 months or no previous surgical sterilization. Women of child
             bearing potential must be willing to use an effective contraceptive measure while on
             study.

          7. Patient or patient's legal representative, parent(s) or guardian able to sign informed
             consent.

          8. Patients must be off any prior chemotherapy, radiotherapy, or other investigational
             therapy within 2 weeks prior to start treatment

        Exclusion Criteria:

          1. Positive for HIV, HBsAg, HCV or other viral hepatitis or cirrhosis from any cause

          2. Active or prior CNS leukemia, unless in complete remission for at least 2 months.

          3. History of serious chronic mental disorder or drug-abuse accompanied by documented
             problems of compliance with therapeutic programs.

          4. Uncontrolled infection

          5. Grade III, IV graft versus host disease (GVHD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>shatha farhan, MD</last_name>
    <phone>313 916 5002</phone>
    <email>SFARHAN1@HFHS.ORG</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>NALINI JANAKIRAMAN, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henry ford hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>shatha farhan</last_name>
      <phone>313-916-5002</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Henry Ford Health System</investigator_affiliation>
    <investigator_full_name>Shatha Farhan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

